Bryostatin 1 (Figure 1 ) is a natural product of the marine Nutt et Schuchter et al., 1991; Gebbia et al., 1992 ; invertebrate Bugula neritina, of the phylum Ectoprocta (Pettit Kennedy et al., 1992; Al-Katib et al., 1993; Mohammed et et al., 1982) . It is the prototype of a 20-member family of al., 1993). Bryostatin 1 enhances neutrophil phagocytic funcmacrocyclic lactones, the principal cellular effect of which is tion (Berkow and Kraft, 1985; May et al., 1987) and activation of protein kinase C (PKC; Berkow and Kraft, 1985; Fields et al., 1988) .
n Bryostatin 1 has a number of anti-tumour cell effects, including the induction of differentiation of leukaemia and lymphoma cell lines and in vitro anti-tumour activity against lung, breast and renal carcinoma, melanoma and ovarian sarcoma as well as lymphoma and leukaemia cell lines. Most of the cell lineages which respond to bryostatin 1 in vitro also respond in vivo, and bryostatin 1 is also active in xenografts bearing drug-resistant P388 leukaemia (NCI Anti-tumour Screening Program; Pettit et al., 1982; Kraft et al., 1986 Kraft et al., , 1987 Kraft et al., , 1989 Dell'Aquilla et al., 1987; Kiss et al., 1987; Stone et al., 1988; Warren et al., 1988; Williams et al., 1988; Dale and Gescher, 1989; Gignac et al., 1990; Jones et al., 1990;  activates tumour antigen-stimulated T cells, which can then induce tumour regression following adoptive transfer (Tuttle et al., 1992) . The combination of bryostatin 1 with cytotoxic drugs increases or restores drug sensitivity. Mohammed et al. (1994) showed that the combination of vincristine with bryostatin 1 cured mice bearing xenografts of neoplastic B cells derived from human Waldenstrom's macroglobulinaemia, and Basu et al. (1990) found that bryostatin 1 restored the sensitivity of cisplatin-resistant cervical carcinoma cell lines.
Bryostatin 1 is associated with indirect stimulation of haempoiesis. The expansion of granulocyte-macrophage colony forming units (CFU-GM) (myeloid progenitor cells) and erythrocyte colony-forming units (CFU-E) (erythroid precursors) stimulated by granulocyte-macrophage colony-stimulating factor (GM-CSF), macrophage colony-stimulating factor (M-CSF) and IL-3 is amplified in the presence of bryostatin 1 Leonard et al., 1988; Sharkis et al., 1990; McCrady et al., 1991; Gebbia et al., 1992; Whetton et al., 1994) .
The preclinical investigation of bryostatin 1 showed that it is active at extremely low concentrations. In rodents the LD,o was 0.029 mg kg-' and the LD50 was 0.068 mg kg-'. Follow- ing treatment the animals exhibited lethargy, unsteadiness and haematuria. There was a significant reduction in platelet and lymphocyte counts, and rats which died within 24 h were found to have pulmonary, muscular, thymic and perivascular haemorrhage. In addition, the liver and spleen increased in weight on treatment.
There are no pharmacokinetic data on bryostatin 1. However, using a bioassay based on the induction of a neutrophil oxidative burst by bryostatin 1, Berkow et al. (1993) showed that 90% of serum bryostatin 1 bioactivity was lost within 2.5 min of injection into mice.
Two phase I trials of bryostatin 1 have been completed. The first (Prendiville et al., 1993) involved the administration of bryostatin 1 in 60% ethanol over 1 h every 2 weeks for three cycles. The drug was infused with normal saline to reduce phlebitis. Nineteen patients entered the trial and the maximum tolerated dose was limited to 35 fg m-2 by cumulative myalgia. Haematological toxicity was only seen at the highest dose level (65 tLg m-2) and included a reduction in platelet and lymphocyte count which recovered within a week and a reduction in neutrophil count which recovered within 24 h.
The second phase I trial (Philip et al., 1993) involved the administration of bryostatin 1, dissolved in PET, over 1 h, weekly for 3 weeks every month. Again, myalgia was the dose-limiting toxicity and the maximum tolerated dose was 25 gg m-2. In this trial 50% of the patients treated at the highest dose level (50 gig m-2) developed significant increases in plasma TNF-x and IL-6 concentrations at 2 and 24 h after treatment respectively. Two patients with metastatic melanoma had partial remissions lasting for 6 weeks and more than 10 months. Of particular importance, the infusion of the PET formulation of bryostatin 1 over 1 h was associated with five cases of chest pain and two cases of cardiac dysrhythmia.
There are some data derived from murine models of lymphoma and melanoma to suggest that greater anti-tumour activity is seen when bryostatin I is administered over longer periods (Schuchter et al., 1991; Hornung et al., 1992) . Since the protocols of the first phase I trials involved the administration of bryostatin 1 over 1 h, this phase I trial was designed to investigate the toxicity and tolerability of bryostatin 1 when administered over 24 h, once a week for 8 weeks. To reduce the frequency of ethanol-related phlebitis, the solvent PET was used to dissolve the bryostatin 1. Additional studies were performed to address the following issues: * Bryostatin 1 is immunomodulatory in rodents. Is (Philip et al., 1993) Figure 2a and b respectively.
PKC activity cannot be measured in frozen samples (data not shown), and therefore all samples had to be processed immediately after they were taken from the patient. These logistic difficulties restricted the measurement of PKC to the first 4 h and the last hour of bryostatin infusion.
Assessment of serum TNF-c and IL-6 concentrations The serum concentrations of IL-6 and TNF-x were measured in nine patients who received between 25 and 50 pg bryostatin-I m-2 per week. Venous blood was taken at 0, 0.5, 1, 2, 4, 6, 8 and 24 h after the initiation of bryostatin 1 administration, centrifuged immediately and the buffy coat removed. Serum was stored in aliquots at -30°C to -80°C until required for analysis. In addition, the serum concentrations of IL-6 and TNF-a were measured in samples taken from 11 patients who, during the previous phase I trial, had received up to 65 iLg m-2 per dose over 1 h (Prendiville et al., 1993) . The samples had been stored between -30°C and -800C.
Serum IL-6 and TNF-x were assayed using a sandwich technique (Lamb, 1992 ) that uses highly specific human monoclonal antibodies directed against the cytokines and a -4-Pt 1-1 Phase I trial of bryosbtin 1 G C Jayson et al 463 which gives chemilumimetric end points. All samples were assayed in duplicate with standard curve samples. Plates were developed using the Amerlite buffer and tablet system and read on Amerlite-enhanced luminescence microtitre plate reader (Amersham International, UK). The standard curve had a range of 31.5-2000 ng ml-' and results were analysed by either Titersoft or Grafit software packages.
LAK cell assay
Informed consent was given by seven patients for 40 ml of blood to be taken before treatment and at 2 h and 24 h during the first four cycles of treatment.
Each sample of heparinised venous blood was centrifuged on lymphocyte separation medium (Flow Laboratories), washed twice and resuspended in RPMI-1640 (Gibco) containing 10% heat inactivated human AB serum (Gibco). The PBMCs were frozen in 10% dimethylsulphoxide (DMSO)-fetal calf serum in liquid nitrogen for lymphokine-activated killer (LAK) cell and proliferation assays.
To measure LAK-cell activity frozen PBMCs were thawed and incubated in 24-well plates (Becton-Dickinson) for 4 days at 2 x 106 cells ml-' with or without IL-2 at 200 IU ml'. They were then incubated in round-bottomed 96-well plates ( For each administration of bryostatin 1, pre-and ontreatment samples were thawed and assayed in parallel. The right-hand axis of Figure 3 shows the differences in specific cytotoxicity between cells at a ratio of 20 effector cells to one target cell treated with IL-2 and cells at the same effector-target ratio but without IL-2.
IL-2 induced PBMC proliferation assay PBMCs were thawed and cultured in round-bottomed 96-well plates (Nunc) over 3 or 4 days with or without IL-2 at Red cell studies In one patient red cell kinetics was studied the week before and the week after the administration of bryostatin 1 to determine the effect on erythrocyte distribution and survival. Ethical committee approval and an ARSAC licence were obtained and the patient gave informed consent. Red cells were labelled with 5'Cr by the ICSH method (Bentley and Miller, 1986 ) and returned to the patient. Samples of 2 ml of peripheral venous blood were taken at various time points, lysed with saponin and the radioactivity of the sample measured using an automated counting system to determine the remaining amount of 5'Cr. The haematocrit was measured on each occasion and the counts expressed per 2 ml of packed cells. Curves of red cell survival were plotted for the week before and the week after bryostatin 1 infusion. To determine whether bryostatin 1 increased the elution of 51Cr from labelled erythrocytes two further samples of whole Time (min) Figure 4 Change in radiolabelled red cell uptake in the livers of a patient receiving bryostatin 1 (0) and a patient not receiving bryostatin 1 (0). blood were taken before and during the treatment. They were incubated at room temperature for 48 h, centrifuged and the plasma counted. This showed that bryostatin 1 did not increase the rate of elution of label from the red cells.
On aKamofsky performance status at entry to the study. 1  2  3  1  2  3  1  2  3  25  8  50  12  12  2  15  6  1  25  1  0   35  8  35  5  10  5  7  5  2  1 1  2  0  50  3  11  4  0  3  3  3  2  5  0  0  Total  19  96  21  22  10  25  14  5  41  3  0 aNumber of patients who received treatment at the dose level.bNumber of cycles of treatment at a particular dose level associated with a particular grade of toxicity. This was symptomatic and was not associated with bleeding, hypotension or haemodilution from the saline infusion. The anaemia occurred during the interval between the first and second blood samplings, suggesting that the blood sampling itself was not responsible for the decrease in haematocrit. In order to investigate the cause of the anaemia, the elimination of 5'Cr-radiolabelled red cells was monitored during the week before and the week after bryostatin 1 infusion. One patient (no. 6) was treated with bryostatin 1 at 25 fig m2 24 h'. These studies showed that red cell survival was not reduced by bryostatin 1 infusion if the samples were corrected for PCV ( Figure 5 ). In the same patient the distribution of 9'Tc-labelled red cells in the heart (representing a blood pool), left kidney, spleen and the liver was followed with a gamma-camera. This showed that there was a steady uptake of labelled red cells in the liver over the first hour of the infusion compared with the hepatic uptake of radiolabelled red cells in another patient who was not receiving bryostatin 1 (Figure 4 ). There were no significant changes in red cell uptake in the spleen, kidney or heart. These preliminary data suggest that the anaemia associated with bryostatin 1 infusion is due to the sequestration of erythrocytes in the liver during the first hour of infusion.
Protein kinase C activity Protein kinase C concentrations were measured in three patients who were treated with bryostatin 1 25 jig m-2 24 h-1.
The concentration of total PKC was measured during the first cycle of treatment for the first patient and during the first three cycles of treatment for the second patient. Active PKC was measured during cycles 4 and 5 for the second patient and the first two cycles for a third patient. Active PKC was also measured in a normal woman, who acted as a control. This showed that both total protein kinase C ( Figure  2a There were no consistent changes in either total or activated PKC between the patients. We anticipated that there would be a depletion of PKC after 24 h of treatment, but this was not seen. The sequestration of red cells in the liver and the rapid disappearance of circulating lymphoma cells in patients receiving bryostatin 1 for non-Hodgkin's lymphoma suggest that bryostatin 1 causes sequestration of circulating blood cells. This would affect the interpretation of the PKC data since the cells undergoing the largest change in PKC in response to bryostatin 1 might marginate or leave the circulation. That this is not the case for all cells in the circulation is demonstrated by the LAK data. Clearly, the optimum method to resolve this problem would be to measure the PKC activity in tumour tissue.
IL-6 and TNF-c
The serum concentration of IL-6 and TNF-a was measured in nine patients in this trial and a further 11 patients from a previous trial. The patients included from this trial were the two women who received bryostatin 1 25 fig m2 24 h-' and who responded to the treatment (nos. 3 and 4), four women treated at 35 figm-224h-' (nos. 10, 11, 12 and 16) and the three patients treated at 50 isg m2 24 h'. Only one patient from the previous trial had an increased serum concentration of IL-6, and no patients had a measurable serum TNF-< concentration. Sera from three patients who had received bryostatin 1 over 1 h at 65 jig m-2 per dose showed no change in IL-6 and TNF-a concentrations.
LAK and PBMC proliferative changes in patients treated with bryostatin 1 LAK-cell and IL-2-induced PBMC proliferation were measured during the first four cycles of treatment in seven patients who received treatment at either 35 or 50 tLg m-2 24 h-' (nos. 11, 12, 13, 15, 16, 17 and 18) . This showed that there was a significant increase in both parameters during treatment, although the proliferative response declined during the study period (Figure 3) . The major change in immune function is seen during the first infusion. There was no evidence to suggest that later cycles were immunomodulatory, although the data do not exclude this (for further discussion see Scheid et al., 1994) Responses Partial responses were seen in one patient with ovarian carcinoma and another with low grade non-Hodgkin's lymphoma, and minor responses were seen in one patient with ovarian carcinoma and another with low-grade non-Hodgkin's lymphoma.
The patient (no. 3) with ovarian carcinoma who had a partial response after bryostatin 1 had been treated previously with a platinum-containing drug regimen for stage III moderately differentiated ovarian carcinoma. This treatment induced a pathological complete remission. She developed recurrent disease in her liver 2 years later and was treated with oral melphalan. Her disease was stable after treatment with melphalan, but 3 months later she developed progressive disease in the adnexae that was palpable and progressive disease around her liver that was detected by computerised tomographic (CT) scan. The clinical measurements of the patient's palpable disease had reduced by 50% after 4 weeks of bryostatin I treatment, and a partial response of all disease sites was confirmed radiologically (CT scan) after 8 weeks. The patient's disease progressed 4 months later, but it was felt inappropriate to offer further treatment with bryostatin 1 as she had developed CTC grade 3 myalgia after the eighth treatment. She was then treated with oral tamoxifen (20 mg day-'), a potent protein kinase C antagonist (Gescher, 1992), and after 6 months she had attained a radiological (CT scan) partial response. She has now developed progressive disease after 14 months of treatment with oral tamoxifen.
A second patient (no. 4) had stage IV poorly differentiated ovarian carcinoma and was treated with a platinumcontaining regimen. This afforded a radiological partial response of 10 months' duration. She developed progressive disease in the omentum and was treated with oral melphalan, but her disease progressed 3 months after completing the melphalan. She was then treated with 25 gg m2 24 h-' bryostatin 1, and after 8 weeks she had attained a radiological minor response (CT scan) that was sustained for 2 months. At progression she was treated with intravenous paclitaxel, resulting in a further minor response of 4 months' duration. When her disease progressed in the liver she was treated with oral tamoxifen 20 mgday-' and is still alive with clinically stable disease 10 months later.
One patient with low-grade non-Hodgkin's lymphoma attained a partial remission of palpable disease which was maintained for 4 months before his disease progressed again. He had been treated previously with two courses of oral chlorambucil followed by a course of CVP (cyclophosphamide, vincristine and prednisolone) before entering this trial at the third recurrence of his disease. Both this patient and another patient with low-grade non-Hodgkin's lymphoma had a greater than 50% reduction in circulating lymphoma cells in the peripheral venous blood within 24 h of commencing bryostatin 1 treatment.
Discussion
The aim of the trial was to identify the tolerability and toxicity of bryostatin 1 when given by peripheral venous infusion over 24 h, once a week for 8 weeks. Myalgia was the dose-limiting toxicity, and the maximum tolerated dose was 25 Lg m-2 per week. Eight patients were treated with this dose, although patient 8 was not evaluable for toxicity as her liver function tests were abnormal on the day of entry into the study. A further patient (no. 7) was unable to continue the study because of poor venous access even though she was unaffected by myalgia. Thus, four of six patients completed treatment at this dose level, fulfilling the criteria for the definition of the maximum tolerated dose.
The mechanism of the myalgia is unknown. Although data from magnetic resonance studies (Hickman et al., 1993) suggest that the myalgia may be caused by vascular changes, patients reported an improvement in symptoms on exercise and the serum creatinine kinase concentrations were normal even in patients with severe myalgia. In addition, electromyography was normal in patients tested during our previous phase I trial (Prendiville et al., 1993) .
Thrombophlebitis was a common complication of the administration of bryostatin 1 in an ethanol diluent (Prendiville et al., 1993) , and to reduce the frequency of phlebitis the diluent was changed to PET (60% polyethylene glycol, 30% ethanol, 10% Tween 80). Despite this, most patients developed at least grade 1 phlebitis, which was probably due to venous stasis incurred through patients sleeping on their arms.
In this trial 15 patients developed CTC grade 1 anaemia within 1 h of commencing the infusion which was associated with a temporary reduction in PCV ( Figure 5) frequency of liver function test abnormalities and the sequestration of red cells in the liver suggests that bryostatin 1 may cause a change in hepatocyte function, perhaps associated with a change in expression of cell adhesion molecules, but this has not been investigated.
Protein kinase C
The family of protein kinase C enzymes consists of 12 serine/ threonine kinase isoenzymes that influence proliferation and differentiation through their role in the second messenger cascade (Gescher, 1992; Dekker and Parker, 1994) .
Protein kinase C can be activated by endogenous ligands such as diacyl glycerol, calcium and phospholipid or modulated by drugs including doxorubicin and tamoxifen (Gescher, 1992) . The prototypic pharmacological activators of PKC are the phorbol esters, of which the most potent is phorbol myristate acetate (PMA). This induces the cytostasis of MCF-7 breast, A431 epidermal and A549 lung carcinoma (Gescher, 1985) and the differentiation of a number of leukaemic cell lines in vitro, but promotes tumour growth in the Sencar mouse model (Hennings et al., 1987) , which is thought to be mediated by the sustained activation of PKC.
Bryostatin 1 is also a PKC activator but does not promote tumour formation and in some models antagonises the effects of PMA. Recent data suggest that bryostatin 1 and PMA affect certain isoenzymes of PKC in different ways (Szallasi et al., 1994; Stanwell et al., 1994) . Twenty-four-hour exposure to PMA is associated with sustained activation of PKC a and P in fibroblasts whereas bryostatin 1 induces significant down regulation of PKC a and P (Isakow et al., 1993) . In view of this we anticipated that the PBMC taken from patients would have increased PKC activity in the first hour of treatment but that this would be significantly reduced by the end of the infusion.
To our knowledge, PKC has not been measured in humans before. These preliminary data show that the total and active PKC concentrations in the PBMCs of patients were modulated by bryostatin 1 treatment when compared with the PKC activity in the PBMCs of the normal woman who acted as a control. There were no consistent patterns of PKC activation between patients. In particular, there were no data to suggest down-regulation of total or active PKC by the end of the infusions. This may be due to the selective down-regulation of only some of the PKC isoenzymes by bryostatin 1, which would be undetectable by our assay system. Two women with ovarian carcinoma responded to bryostatin 1. Both women had been treated with a platinumcontaining drug regimen and then oral melphalan before receiving bryostatin 1. One woman had a partial response of 4 months' duration and the other had a minor response radiologically. Subsequently, both women developed progressive disease and the woman who had the minor response was treated with paclitaxel. Both are now taking tamoxifen and the first woman attained a partial response before developing progressive disease after 14 months' treatment, and the second woman has clinically stable disease after 10 months' treatment. This is interesting because tamoxifen is a powerful PKC inhibitor (Gescher, 1992) , and therefore these women may have a subgroup of ovarian carcinoma which is sensitive to the manipulation of PKC. Whether bryostatin and tamoxifen modulate the activity of the same isoenzymes of PKC is not known.
Immune function and cytokine studies Bryostatin 1 is immunomodulatory both in vitro and in vivo, but the immune effects in humans are unknown. LAK activity was of particular interest because LAK activity is associated with 25% response rates in patients with renal carcinoma or melanoma (Rosenberg et al., 1987; Negrier et al., 1989) . In the three phase I trials of bryostatin 1, seven patients with renal carcinoma have been treated but none has responded to treatment. One partial and one minor response have been seen in melanoma (Philip, 1993) , but the relevance of LAK activity in these patients is unknown. These data show that bryostatin 1 treatment is associated with a sustained increase in LAK-cell activity during the 4 week study period and a significant increase in the capacity of PBMCs to multiply in response to IL-2, although this declined over the 4 weeks of study. However, Figure 3 shows that the increase in LAK activity occurs during the first cycle of bryostatin 1. Whether subsequent cycles affect LAK activity is not clear from these data. It is possible that the decline in the proliferative response over 3 weeks is due to margination or extravasation of certain lymphocyte populations leading to an apparent reduction in the number or ability of cells to multiply in response to IL-2.
We have shown that bryostatin 1 inhibits LAK activity in vitro but increases LAK activity in vivo (Scheid et al., 1994) . This disparity led us to suspect that an indirect mechanism was responsible for the increased LAK activity in vivo. The mechanism by which bryostatin-l-stimulated CD8+T cells reduced lung metastasis in a murine sarcoma model was shown to be mediated through the release of y-interferon (Tuttle et al., 1992) . However, there was no measurable increase in the concentration of y-interferon in the conditioned medium from patients' PBMCs (data not shown), and the mechanism for LAK cell stimulation in these patients remains unclear. Philip et al. (1993) reported significant increases in the plasma concentration of TNF-a at 2 h and IL-6 at 24 h in 50% of the patients treated with 50 Lg m-2 per dose of bryostatin 1 over an hour. In order to investigate this, we measured the concentration of these cytokines in serum samples taken from 20 patients. Nine of the patients were from this trial (24 h infusion) and 11 were from the first phase I trial (1 h infusion), of whom three patients had received treatment at 65 lag m2 per dose. However, the serum samples from only one patient had raised levels of IL-6. These data suggest that the reported changes in cytokines are not present in all patients treated with high doses of bryostatin 1. Bryostatin 1 is a novel anti-cancer agent that has shown clinical activity with this formulation and which is associated with modulation of protein kinase C activity and immune function in vivo. We recommend that bryostatin 1 is given as a 24 h infusion at a dose of 25 ,ug m-2 per week for 8 weeks and that patients with ovarian carcinoma and low grade non-Hodgkin's lymphoma are entered into phase II trials.
